NCT05679895 - Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions

T-cell Acute Lymphoblastic LeukemiaLymphoblastic T-Cell Lymphoma

Interventions

BIOLOGICAL

CD1a-CAR T

Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express CD1a chimeric antigen receptor administered by intravenous infusion following a dose-escalation approach

Trial Locations (2)

Unknown

RECRUITING

Hospital Clínic, Barcelona

RECRUITING

Hospital Sant Joan de Déu, Barcelona